visitant ::
identificació
|
|||||||||||||||
Cerca | Lliura | Ajuda | Servei de Biblioteques | Sobre el DDD | Català English Español |
Pàgina inicial > Articles > Articles publicats > Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia |
Data: | 2015 |
Resum: | The CD19 marker is expressed on the surface of normal and malignant immature or mature B-cells. On the other hand, immunotherapy involving T-cells is a promising modality of treatment for many neoplastic diseases including leukemias and lymphomas. The CD19/CD3-bispecific T-cell-engaging (BiTE ®) monoclonal antibody blinatumomab can transiently engage cytotoxic T-cells to CD19+ target B-cells inducing serial perforin-mediated lysis. In the first clinical trial, blinatumomab showed efficacy in non-Hodgkin's lymphomas, but the most important trials have been conducted in relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) and in ALL with minimal residual disease. Encouraging reports on the activity of blinatumomab in R/R Philadelphia chromosome-negative B-cell precursor ALL led to its approval by the US Food and Drug Administration on December 3, 2014 after an accelerated review process. This review focuses on the profile of blinatumomab and its activity in R/R ALL. |
Ajuts: | Instituto de Salud Carlos III PI14/01971 Instituto de Salud Carlos III RD-0036-0029 Agència de Gestió d'Ajuts Universitaris i de Recerca 2014SGR225 |
Nota: | This study was supported in part by grants from the Red Temática de Investigación Cooperativa en Cáncer (RTICC, FEDER) (RD12/0036/0029), 2014 SGR225 (GRE) Gener-alitat de Catalunya, and PI14/01971 from Fondo de Investi-gaciones Sanitarias, Instituto de Salud Carlos III, and Obra Social "La Caixa" |
Drets: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. |
Llengua: | Anglès |
Document: | Article ; Versió publicada |
Matèria: | Acute lymphoblastic leukemia ; Relapsed/refractory ; BiTE ® monoclonal antibodies ; Blinatumomab |
Publicat a: | OncoTargets and therapy, Vol. 8 (june 2015) , p. 1567-1574, ISSN 1178-6930 |
8 p, 223.4 KB |